Talphera (NASDAQ:TLPH) Upgraded to “Strong-Buy” at RODMAN&RENSHAW

Talphera (NASDAQ:TLPH) was upgraded by RODMAN&RENSHAW to a “strong-buy” rating in a report issued on Tuesday,Zacks.com reports.

Several other brokerages have also commented on TLPH. Maxim Group raised shares of Talphera to a “strong-buy” rating in a report on Friday, November 8th. HC Wainwright reissued a “buy” rating and set a $6.00 target price on shares of Talphera in a report on Tuesday, January 21st. Finally, Rodman & Renshaw assumed coverage on Talphera in a research report on Tuesday. They set a “buy” rating and a $4.00 price target for the company.

Talphera Trading Down 3.7 %

TLPH opened at $0.70 on Tuesday. Talphera has a 12-month low of $0.50 and a 12-month high of $1.61. The firm has a 50 day moving average of $0.65 and a two-hundred day moving average of $0.81. The firm has a market capitalization of $11.94 million, a PE ratio of -1.02 and a beta of 0.28.

Institutional Trading of Talphera

An institutional investor recently bought a new position in Talphera stock. Rosalind Advisors Inc. bought a new position in shares of Talphera, Inc. (NASDAQ:TLPH) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 758,966 shares of the company’s stock, valued at approximately $650,000. Talphera accounts for about 0.4% of Rosalind Advisors Inc.’s investment portfolio, making the stock its 25th largest holding. Rosalind Advisors Inc. owned approximately 4.47% of Talphera at the end of the most recent quarter. Institutional investors and hedge funds own 37.67% of the company’s stock.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.